SPECIAL BULLETIN COVID-19 #160: Janssen COVID-19 Vaccine HCPCS Code 91303 and 0031A Billing Guidelines

<p>Janssen COVID-19 vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.</p>

Janssen COVID-19 vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. Effective with date of service Feb. 27, 2021, the North Carolina Medicaid and NC Health Choice programs cover Janssen COVID-19 Vaccine (N/A) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code 91303 - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10^10 viral particles/0.5mL dosage, for intramuscular use.

Janssen COVID-19 Vaccine is a preservative-free suspension for injection in a multiple dose vial. It is administered intramuscularly as a single dose (0.5 mL). See full prescribing information for further detail.

The CDC has released Interim Guidance for Immunization Services During the COVID-19 Pandemic. This guidance is intended to help immunization providers in a variety of clinical and alternative settings with the safe administration of vaccines during the COVID-19 pandemic.

If you have any questions about product-specific information, please contact the Immunization Branch help desk at 877-873-6247 and press option 6. 

For Medicaid and NC Health Choice Billing

  • The ICD-10-CM diagnosis code(s) required for billing is/are:  Z23 - Encounter for immunization
  • Providers must bill with HCPCS code: 91303 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10^10 viral particles/0.5mL dosage, for intramuscular use
  • One Medicaid and NC Health Choice unit of coverage is: 0.5 mL (1 dose)
  • The maximum reimbursement rate per unit is: N/A (federally supplied)
  • Providers must bill 11-digit NDCs and appropriate NDC units. The NDCs is/are: 59676-0580-05, 59676-0580-15
  • The NDC units should be reported as "UN1."
  • The fee schedule for the PADP is available on NC Medicaid's PADP web page.

Important Claims Information:

  • Providers must bill with HCPCS code: 0031A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative-free, 5x1010 viral particles/0.5mL dosage, single dose
  • Medicaid and NC Health Choice will reimburse at the Medicare approved COVID-19 vaccination administration rate of $28.39. 
  • Claims must have appropriate NDCs that correspond to the vaccine used for administration and corresponding CPT code.
  • Claims must contain both administration codes and vaccine codes to pay.
  • Vaccine codes should be reported as $0.00.
  • Medicaid and NC Health Choice do not allow copays to be charged for COVID-19 immunization or administrations.
  • COVID-19 vaccines are exempt from the Vaccines For Children (VFC) program
  • Pharmacies may administer Janssen COVID-19 Vaccines to any Medicaid and NC Health Choice beneficiary 18 years and older.  All other vaccines (non-COVID-19 vaccines) that are approved by the NC Board of Pharmacy to be administered by a pharmacist are only permissible to be administered at a pharmacy for Medicaid beneficiaries 19 years and older. 
  • TJ modifier should be appended to all NC Health Choice claims (through 18 years).
  • EP modifier should be appended to all non-NC Health Choice (only Medicaid beneficiaries) younger than 21 years of age.
  • CG modifier should be appended to ALL COVID-19 vaccine AND administration claims submitted by a pharmacy participating in the immunization program.

COVID-19 Vaccine Billing Codes for Medicaid Beneficiaries

Vaccine CPT Codes for ALL Covid-19 Vaccines to Report

Vaccine CPT Code to Report

NDC

CPT Code Description

91300

59267-1000-01,

59267-1000-02,

59267-1000-03

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use

91301

80777-0273-10,

80777-0273-99

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use

91303

59676-0580-05, 59676-0580-15

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10^10 viral particles/0.5mL dosage, for intramuscular use.

Administrative CPT Codes for ALL Covid-19 Vaccines to Bill

Administration CPT Code(s) to Bill

CPT Code Description

0001A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative- free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose

0002A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative- free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose

0011A

Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative- free, 100 mcg/0.5mL dosage; first dose

0012A

Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative- free, 100 mcg/0.5mL dosage; second dose

0031A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative-free, 5x1010 viral particles/0.5mL dosage, single dose

 

Contact

NCTracks Contact Center: 800-688-6696

Related Topics: